Key Insights

Highlights

Success Rate

93% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.4%

2 terminated out of 45 trials

Success Rate

93.3%

+6.8% vs benchmark

Late-Stage Pipeline

7%

3 trials in Phase 3/4

Results Transparency

14%

4 of 28 completed with results

Key Signals

4 with results93% success

Data Visualizations

Phase Distribution

18Total
Not Applicable (6)
P 1 (3)
P 2 (6)
P 3 (1)
P 4 (2)

Trial Status

Completed28
Unknown8
Recruiting4
Withdrawn3
Terminated2

Trial Success Rate

93.3%

Benchmark: 86.5%

Based on 28 completed trials

Clinical Trials (45)

Showing 20 of 20 trials
NCT07110636Not ApplicableRecruiting

Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients

NCT04341792CompletedPrimary

Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient

NCT03163628Not ApplicableCompleted

biomArkers to differeNtiate bacTerial From vIral iNfEctions

NCT06548841Completed

Development and Validation of (Bio)Sensors for the Identification of Pathogens

NCT06178822Recruiting

Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room

NCT06149494Phase 2Completed

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection

NCT04637867Not ApplicableCompletedPrimary

COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO)

NCT04290780CompletedPrimary

COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus

NCT06161454Phase 4Completed

Xofluza-Wearables Feasibility-Study

NCT06379061Completed

Access MeMed BV Assay Clinical Study Collection Protocol - Infectious Adult and Pediatric Cohorts

NCT06286657Not ApplicableRecruitingPrimary

Xanthohumol and Viral Infections (XL)

NCT05712759WithdrawnPrimary

Nosocomial Influenza Surveillance of 2022 - 2027 Seasonal Period

NCT04386460Completed

Covid-19 and Prevention of Malnutrition After Confinement by Dentists

NCT05875961Phase 1Completed

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

NCT04449978Completed

TARGet Kids! COVID-19 Study of Children and Families

NCT05874713Phase 2Completed

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

NCT04380701Phase 1Completed

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults

NCT04664075Terminated

Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)

NCT05069623Phase 1Completed

A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers

NCT04327180CompletedPrimary

PREdiction of DIagnosed Covid-19 infecTion in IUC Patients

Scroll to load more

Research Network

Activity Timeline